Israel - English - Ministry of Health

ferring pharmaceuticals ltd - triptorelin acetate - solution for injection - triptorelin acetate 0.1 mg/ml - triptorelin - triptorelin - ivf

Israel - English - Ministry of Health

medison pharma ltd - triptorelin as acetate - powder and solvent for suspension for injection - triptorelin as acetate 3.75 mg/vial - triptorelin - triptorelin - prostate cancer: treatment of prostate cancer with metastases. patients who have not previously received hormone therapy show a more marked response to the treatment and respond more frequently if the patient has not previously receieved another hormone treatment. precocious puberty: (before 8 years in girls and 10 years in boys). genital and extragenital endometriosis (stage i to stage iv): treatment should not be administered for more than 6 months. it is not recomended to start a second treatment course with triptorelin or another gnrh analogue. treatment of uterine fibromyomas prior to surgery: associated with anaemia ( haemoglobin less than, or equal to 8 g/dl). when a reduction in the size of the fibromyoma is necessary to facilitate or modify the surgical technique: endoscopic surgery, transvaginal surgery. the treatment duration is restricted to 3 months. female infertility: supplementary treatment in combination with gonadotrophins (hmg, fsh, hcg) to induce ovulation with a view to in vitro fertilisa

Israel - English - Ministry of Health

medison pharma ltd - triptorelin as acetate - powder and solvent for solution for injection - triptorelin as acetate 0.1 mg/vial - triptorelin - triptorelin - female infertility: management of ovarian stimulation in association with the gonadotrophins (hmg, fsh, hcg) in view of in vitro fertilisation and embrio transfer (i.v.f.e.t.) and other assisted conception techniques.

Israel - English - Ministry of Health

ferring pharmaceuticals ltd - triptorelin as embonate - powder and solvent for suspension for injection - triptorelin as embonate 11.25 mg - triptorelin - triptorelin - - lowering of sexual hormones and- treatment of advanced hormone-dependent prostate cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - triptorelin acetate, quantity: 100 microgram (equivalent: triptorelin, qty 95.6 microgram/ml) - injection, solution - excipient ingredients: glacial acetic acid; water for injections; sodium chloride - decapeptyl 100 micrograms/1 ml is indicated for down-regulation and prevention of premature luteinising hormone (lh) surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (art).,in clinical trials decapeptyl 100 micrograms/1 ml has been used in cycles where urinary and recombinant human follicle stimulating hormone (fsh) as well as human menopausal gonadotrophin (hmg) were used for stimulation.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

vetoquinol australia pty ltd - triptorelin acetate - misc. intra vaginal/uterine prep/device - triptorelin acetate anthelmintic active 100.0 ug/ml - endocrine system

United States - English - NLM (National Library of Medicine)

allergan, inc. - triptorelin pamoate (unii: 08an7wa2g0) (triptorelin - unii:9081y98w2v) - triptorelin 3.75 mg in 2 ml - trelstar is indicated for the palliative treatment of advanced prostate cancer [see  clinical studies (14) ]. trelstar is contraindicated in individuals with a known hypersensitivity to triptorelin or any other component of the product, or other gnrh agonists or gnrh [see warnings and precautions (5.1) ]. risk summary based on findings in animal studies and mechanism of action, trelstar can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1) ] . expected hormonal changes that occur with trelstar treatment increase the risk for pregnancy loss. in animal developmental and reproductive toxicology studies, daily administration of triptorelin to pregnant rats during the period of organogenesis caused maternal toxicity and embryo-fetal toxicities, including loss of pregnancy, at doses as low as 0.2, 0.8, and 8 times the estimated human daily dose based on body surface area. advise pregnant patients and females of reproductive potential of the potential risk to the fetus. dat

United States - English - NLM (National Library of Medicine)

azurity pharmaceuticals, inc. - triptorelin (unii: 9081y98w2v) (triptorelin - unii:9081y98w2v) - triptorelin 22.5 mg in 2 ml - triptodur is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (cpp). - hypersensitivity: triptodur is contraindicated in individuals with a known hypersensitivity to triptorelin, any other component of the product, or other gnrh agonists or gnrh [see adverse reactions (6.2)] . - pregnancy: triptodur may cause fetal harm [see use in specific populations (8.1)] . risk summary triptodur is contraindicated in women who are pregnant [see contraindications (4)] since expected hormonal changes that occur with triptodur treatment increase the risk for pregnancy loss. available data with triptorelin use in pregnant women are insufficient to determine a drug-associated risk of adverse developmental outcomes. based on mechanism of action in humans and findings of increased pregnancy loss in animal studies, triptodur may cause fetal harm when administered to pregnant women. advise pregnant women of the potential risk to a fetus. the estimated background risk of m

Israel - English - Ministry of Health

ferring pharmaceuticals ltd - triptorelin as acetate - powder and solvent for suspension for injection - triptorelin as acetate 3.75 mg/vial - triptorelin - triptorelin - lowering sexual hormones, prostate cancer, endomedtriosis, uterus myomatosus, fertility treatment ivf. central precocious puberty.

Singapore - English - HSA (Health Sciences Authority)

ipsen pharma singapore pte. ltd. - triptorelin pamoate eqv. triptorelin - injection, powder, for suspension, extended release - 11.25 mg/vial - triptorelin pamoate eqv. triptorelin 11.25 mg/vial